The clinical information you need, at your fingertips.

Medical News for You

J Am Heart Assoc

ADA 2026: Fewer deaths and clots observed with GLP‑1s in obesity with autoimmune disease

Real-world data show reduced thromboembolism, ED visits, and mortality with GLP‑1 therapy. . .

Ann Oncol

GLP-1 drugs linked to lower cancer risk in adults without diabetes

Large real-world study suggests meaningful reductions in obesity-related cancers beyond weight control. . .

Lancet

EULAR 2026: CD40L inhibitor improves lupus disease control in phase 3 trial

Dapirolizumab pegol significantly increased clinical response rates and showed steroid-sparing potential in patients with moderate-to-severe systemic lupus erythematosus. . .

ADA 2026

Monthly GLP-1 shows strong weight loss in phase 2b trials

Pfizer’s investigational berobenatide demonstrated substantial weight loss, HbA1c reductions, and favorable tolerability across weekly and monthly dosing regimens. . .

JAMA

Oral orforglipron improves glycemic control in insulin-treated type 2 diabetes

Up to 70% of patients achieved HbA1c below 7% without increased hypoglycemia risk. . .

Lancet

ADA 2026: First-line retatrutide drives normal A1C in nearly half of T2D patients

Phase 3 data show the investigational triple agonist cut A1C by up to 2.0% and brought nearly half of drug-naive patients to normal glycemic levels, while separate results show meaningful reductions in sleep apnea severity and knee pain. . .

N Engl J Med

10h

ADA 2026: Dual-agonist survodutide delivers double-digit weight loss in phase 3 obesity trial

But GI adverse events led to discontinuation in 1 in 5 patients. . .

ADA 2026

10h

Oral GLP-1 shows consistent weight loss across menopause stages

Post hoc ADA 2026 analysis highlights robust efficacy of orforglipron in women, including those with type 2 diabetes. . .

FDA

11h

FDA approves interchangeable ranibizumab biosimilar for retinal diseases

Ranluspec is the first interchangeable ranibizumab biosimilar available in both vial and prefilled syringe formulations. . .

The clinical information you need, at your fingertips.

EPOCRATES CME

Clinical FAQs